Leishmaniasis remains one of the fatal diseases worldwide and the conventional antileishmanial therapies are associated with several drawbacks. Therefore, there is a need to develop new antileishmanial strategies. Biogenic silver and gold nanoparticles possess broad-spectrum antimicrobial activities and could be future alternatives to current antimicrobial agents. In this report, we present a simple and green approach to synthesize silver and gold nanoparticles with efficient biological activities. Phytochemicals from Sargentodoxa cuneata were used to reduce and stabilize the silver and gold ions into metallic nanoparticles. The synthesized nanoparticles were characterized by UV-visible spectroscopy (surface plasmon resonance), X-ray diffraction analysis (crystallinity), high-resolution transmission electron microscopy (size and morphology), energy dispersive X-ray (elemental composition) and FTIR (surface functionalities). Under optimized conditions, the synthesized silver nanoparticles were spherical in shape, of small sizes (3–8 nm) and well dispersed. However, the gold nanoparticles were mostly hexagonal in shape with approximate sizes from 15 to 30 nm. Promising antileishmanial activity was shown by silver and gold nanoparticles with an IC50 value of 4.37 and 5.29 μg mL−1 respectively. Silver nanoparticles also exhibited significant antibacterial activity against Staphylococcus aureus (32 ± 3 mm), Pseudomonas araginosis (16 ± 2 mm), and Bacillus subtilis (18 ± 2 mm). The depicted biological activities of nanoparticles are not simply due to the capped silver and gold atoms but also to their surface macromolecules. Thus, the use of Sargentodoxa cuneata as a reducing and capping agent will retain its biological activity even after the depletion of maintained silver and gold. The findings of this study indicate that these nanoparticles could be an alternative, safe, and effective source of antileishmanial agents.
The gut microbiota that inhabit our gastrointestinal tract are well known to play an important role in maintaining human health in many aspects, including facilitating the digestion and absorption of nutrients, protecting against pathogens and regulating immune system. Gut microbiota dysbiosis is associated with a lot of diseases, such as inflammatory bowel disease, allergy, obesity, cardiovascular and neurodegenerative diseases and cancers. With the increasing knowledge of the microbiome, utilization of probiotic bacteria in modulating gut microbiota to prevent and treat a large number of disorders and diseases has gained much interest. In recent years, aided by the continuous development of tools and techniques, engineering probiotic microbes with desired characteristics and functionalities to benefit human health has made significant progress. In this paper, we summarize the recent advances in design and construction of probiotics as living diagnostics and therapeutics for probing and treating a series of diseases including metabolic disorders, inflammation and pathogenic bacteria infections. We also discuss the current challenges and future perspectives in expanding the application of probiotics for disease treatment and detection. We intend to provide insights and ideas for engineering of probiotics to better serve disease therapy and human health.
7 May 2013 in Journal of the Science of Food and Agriculture
Metabolic engineering is a powerful tool for the sustainable production of chemicals. Over the years, the exploration of microbial, animal and plant metabolism has generated a wealth of valuable genetic information. The prudent application of this knowledge on cellular metabolism and biochemistry has enabled the construction of novel metabolic pathways that do not exist in nature or enhance existing ones. The hand in hand development of computational technology, protein science and genetic manipulation tools has formed the basis of powerful emerging technologies that make the production of green chemicals and fuels a reality. Microbial production of chemicals is more feasible compared to plant and animal systems, due to simpler genetic make-up and amenable growth rates. Here, we summarize the recent progress in the synthesis of biofuels, value added chemicals, pharmaceuticals and nutraceuticals via metabolic engineering of microbes.